rosiglitazone has been researched along with Neurodegenerative Diseases in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Botros, M; Kinarivala, N; Suh, JH; Trippier, PC; Webb, P | 1 |
| Braczko, A; Jablonska, P; Jedrzejewska, A; Krol, O; Mierzejewska, P; Pierzynowska, K; Podlacha, M; Slominska, EM; Smolenski, RT; Tomczyk, M; Wegrzyn, G | 1 |
| Chen, Y; Dai, Y; Gao, H; Huang, Y; Jin, R; Mo, D; Yan, Q; Zhang, C; Zhang, L | 1 |
| Chaudhary, T; Kumar, A; Mishra, J | 1 |
| Neuhaus, W; Thal, SC | 1 |
| Bronfman, M; Fuentealba, RA; Fuenzalida, K; Inestrosa, NC; Martinez, G; Piderit, D; Quintanilla, R; Ramos, P | 1 |
1 review(s) available for rosiglitazone and Neurodegenerative Diseases
| Article | Year |
|---|---|
The blood-brain barrier as a target in traumatic brain injury treatment.
Topics: Blood-Brain Barrier; Brain Edema; Brain Injuries; Cell Hypoxia; Humans; Hypoglycemic Agents; Inflammation; Myosin-Light-Chain Kinase; Neurodegenerative Diseases; Neuroprotective Agents; Peroxisome Proliferator-Activated Receptors; Pioglitazone; Receptors, Glucocorticoid; Rosiglitazone; Thiazolidinediones | 2014 |
5 other study(ies) available for rosiglitazone and Neurodegenerative Diseases
| Article | Year |
|---|---|
Pharmacophore elucidation of phosphoiodyn A - Potent and selective peroxisome proliferator-activated receptor β/δ agonists with neuroprotective activity.
Topics: Dose-Response Relationship, Drug; Humans; Hydrocarbons, Iodinated; Molecular Structure; Neurodegenerative Diseases; Neuroprotective Agents; Organophosphorus Compounds; Polyynes; PPAR delta; PPAR-beta; Structure-Activity Relationship | 2016 |
Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington's Disease.
Topics: Animals; Disease Models, Animal; Huntington Disease; Mice; Mice, Transgenic; Muscle, Skeletal; Neurodegenerative Diseases; PPAR gamma; Rosiglitazone | 2022 |
Inhibition of ACSL4 ameliorates tubular ferroptotic cell death and protects against fibrotic kidney disease.
Topics: Acute Kidney Injury; Animals; Cell Death; Epithelial Cells; Fibrosis; Humans; Mice; Neurodegenerative Diseases; Rosiglitazone | 2023 |
Rosiglitazone synergizes the neuroprotective effects of valproic acid against quinolinic acid-induced neurotoxicity in rats: targeting PPARγ and HDAC pathways.
Topics: Animals; Body Weight; Brain; Disease Models, Animal; Drug Synergism; Histone Deacetylase Inhibitors; Histone Deacetylases; Huntington Disease; Male; Maze Learning; Motor Activity; Neurodegenerative Diseases; Neuroprotective Agents; Neurotoxicity Syndromes; PPAR gamma; Quinolinic Acid; Rats, Wistar; Rosiglitazone; Signal Transduction; Thiazolidinediones; Valproic Acid | 2014 |
Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis.
Topics: Amyloid beta-Peptides; Animals; Apoptosis; Cell Differentiation; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Ganglia, Spinal; Hippocampus; Hydrogen Peroxide; Hypoglycemic Agents; Mice; Mitochondria; Nerve Growth Factor; Neurodegenerative Diseases; Neuroglia; Neurons; Oxidants; Oxidative Stress; PC12 Cells; PPAR gamma; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Rats; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones | 2007 |